Close

Gilead Sciences and WuXi PharmaTech Announce Collaboration for a Dedicated Analytical and Stability

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Gilead Sciences, Inc., and WuXi PharmaTech (Cayman) Inc. (NYSE: WX), today announced that they have entered into a strategic partnership to conduct analytical and stability studies of small-molecule new chemical entities to support global marketing applications and commercial products.
Under the agreement, WuXi will equip and operate a dedicated, fully cGMP-compliant 12,500-square-foot analytical testing facility in Shanghai. The facility will provide analytical and stability services, including analytical method development, transfer and validation for IND/NDA submissions; commercial API and drug product testing; stability studies of APIs, drug products for registration, and commercial products; and reference standard qualification.
"This strategic partnership further strengthens our close, broad-based collaboration with Gilead over many years," said Ge Li, PhD, Chairman and CEO of WuXi PharmaTech. "WuXi is determined to enable our innovative partners like Gilead through our open-access R&D platform, and we are very honored to help advance some of the most innovative medicines faster to patients."
"The opening of this analytical and stability testing center is an important milestone in the ongoing long-term relationship between Gilead and WuXi," said Bob Miller, Vice President of Quality Assurance – Gilead Sciences.

Latest stories